N. Henig

发表

Advancing clinical trial design in pulmonary hypertension

M. Rahbar, M. Wilkins, L. Harnisch, 2013, Pulmonary circulation.

Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction

F. Martinez, G. Raghu, J. Behr, 2015, European Respiratory Journal.

Biomedical ethics and the withdrawal of advanced life support.

T. Raffin, J. Faul, N. Henig, 2001, Annual review of medicine.

Conflict over communication and unprofessional staff behavior: a common source of dissatisfaction during the withdrawal of care?

T. Raffin, N. Henig, D. C. McGee, 2001, Critical care medicine.

Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.

G. O’Toole, G. Anderson, D. Macleod, 2013, Pathogens and disease.

Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses.

W. Henderson, M. C. Liu, M. Liu, 2000, American journal of respiratory and critical care medicine.

A hypertrophied bronchial circulatory system may participate in gas exchange

R. Glenny, M. Aitken, N. Henig, 1998, The Lancet.

Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.

B. Morrissey, D. Bilton, M. Gotfried, 2006, Chest.

Lung transplantation: a decade of experience.

R. Whyte, S. Moffatt, B. Reitz, 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Inflammatory and Microbiologic Markers in Induced Sputum following IV Antibiotics in Cystic Fibrosis

R. Gibson, F. Accurso, P. Zeitlin, 2003 .

Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.

D. Kohan, M. Allard, D. Pollock, 2012, The American journal of cardiology.

Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.

O. Ben‐Yehuda, M. Littman, N. Henig, 2012, Journal of the American College of Cardiology.

Human Papillomavirus and Cardiovascular Disease

O. Ben‐Yehuda, M. Littman, N. Henig, 2012 .

Sinus disease in cystic fibrosis

N. Henig, Gordon K. Mak, 2001, Clinical reviews in allergy & immunology.

Genetic medicines for CF: Hype versus reality

J. Davies, S. Hyde, D. Gill, 2016, Pediatric pulmonology.

Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.

R. Gibson, F. Accurso, P. Zeitlin, 2003, American journal of respiratory and critical care medicine.

Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis

J. Burns, M. Tonelli, M. Aitken, 2001, Thorax.

Risk factors for death of patients with cystic fibrosis awaiting lung transplantation.

S. Xie, D. Lipson, R. Kotloff, 2006, American journal of respiratory and critical care medicine.

Prevalence of Bronchiolitis Obliterans Syndrome (BOS) Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in the USA, Europe and Japan

N. Henig, D. Kappeler, E. Hofstetter, 2019, Blood.

Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.

P. Dřevínek, J. Elborn, K. De Boeck, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.

P. Kao, S. Ruoss, S. Jacobs, 2006, Chest.

Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.

S. Lewis, D. E. Tullis, J. Lipuma, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine

J. Elborn, N. Henig, J. Elborn, 2010, Expert opinion on pharmacotherapy.

Mechanisms of hypoxemia.

D. Pierson, N. Henig, 2000, Respiratory care clinics of North America.

Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis

T. Ritsema, W. Beumer, Patricia Biasutto, 2019, PloS one.

The Cystic Fibrosis-Like Airway Surface Layer Is not a Significant Barrier for Delivery of Eluforsen to Airway Epithelial Cells.

W. Beumer, B. Button, M. D. de Jager, 2019, Journal of aerosol medicine and pulmonary drug delivery.

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis

J. Clancy, J. Bolognese, J. Nick, 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection

S. Lewis, J. Lipuma, E. Tullis, 2012 .

WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: final results from a randomized, placebo-controlled trial

S. Lewis, J. Lipuma, E. Tullis, 2012 .

POS1128 ZETOMIPZOMIB (KZR-616) TREATMENT RESULTS IN CLINICALLY MEANINGFUL RENAL RESPONSES IN PATIENTS WITH LUPUS NEPHRITIS

N. Henig, R. Leff, A. Saxena, 2023, Annals of the Rheumatic Diseases.

POS0695 KZR-616, A SELECTIVE IMMUNOPROTEASOME INHIBITOR FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COMPLETED DOSE ESCALATION PHASE 1B PORTION OF THE MISSION STUDY

R. Furie, C. Kirk, Jinhai Wang, 2021 .